硕迪生物(GPCR.US)股价今日盘中大跌6.54%,引发市场关注。
从公开消息来看,硕迪生物是一家临床阶段的生物制药公司,主要产品为治疗糖尿病和肥胖症的口服候选药物GSBR-1290。但就目前来看,该公司并未传出任何重大利好消息,导致投资者对公司前景缺乏信心,加之部分资金选择了获利了结,因此可能是造成股价大跌的主要原因。
不过值得注意的是,该股近期财务数据良好,去年全年虽然净亏损达1.23亿美元,但营收有望在新药上市后显著改善。另外机构给予的评级均为买入,显示出对公司长期前景的乐观预期。因此,只要公司研发顺利,未来随着新药问世,股价或将迎来反弹。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.